In this phase 2 study, researchers sought to determine whether cytoreductive treatment with rituximab followed by epcoritamab would deepen responses and lower risk of cytokine release syndrome.

“In our real-world experience, [Yescarta] in relapsed or refractory follicular lymphoma showed durable responses and a ...

Roche (ROG: SIX) has unveiled a fresh wave of data for Lunsumio (mosunetuzumab), underscoring the Swiss pharma major’s ...

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the ...

Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment option ...

Bristol Myers Squibb (NYSE: BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data highlighting the potential of ...

Roche (RHHBY) announced new data highlighting the potential of Lunsumio, mosunetuzumab, in earlier treatment lines for people ...

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction ...

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction ...

R 2 is the only second-line alternative to chemoimmunotherapy-based treatment for patients with relapsed/refractory ...